Phase III
Gilead announced topline results from the open-label, Phase III SIMPLE trial looking at 5-day and 10-day dosing of the drug in hospitalized patients with severe disease. It also reported positive data from the National Institute of Allergy and Infectious Diseases’ trial of the drug in COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
Sanofi and Regeneron halted a Phase III study of its checkpoint inhibitor Libtayo as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.
About 70% of AD patients have symptoms of agitation, which is marked by emotional distress, aggressive behaviors, disruptive irritability and loss of inhibition.
Avadel Pharma announced positive topline data from its pivotal Phase III REST-ON clinical trial of FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
AstraZeneca and Merck & Co. released more positive data from the Phase III PROfound trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
PRESS RELEASES